Critical Limb Ischemia
Critical limb ischemia (CLI) is a severe obstruction of the arteries that reduces blood flow to the limbs, causing pain and increasing the risk of infection and amputation.
Critical Limb Ischemia: L-PRF Treatment Study
We are investigating the safety of a new treatment using patient-derived fibrin for individuals with critical limb ischemia. The study also looks at its potential effects on limb health and quality of life.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 90 years old?
- Do you have critical limb ischemia (severe blockage of blood flow in the legs)?
- Are you currently pregnant or breastfeeding?
- Is your expected survival time more than 3 years?
- Do you have active cancer (diagnosed within the last 5 years)?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Leukocyte-Platelet Rich Fibrin
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
Katedra i Klinika Chirurgii Ogólnej, Naczyniowej, Endokrynologicznej i Transplantacyjnej
Ochota, Poland
Sponsor: Medical University Of Warsaw
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.